DOCSLIB.ORG

Front Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Front Matter (PDF) CancerResearch AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH December 15, 1998 Volume 58 •Number 24 PP. 5633-5890 ISSN0008-5472 •CNREA 8 AMERICAN ASSOCIATION FOR CANCER RESEARCH 90TH ANNUAL MEETING April 10-14,1999 Pennsylvania Convention Center, Philadelphia, PA SPECIAL EVENTS (Topics with Confirmed Speakers/Organizers in Parentheses) EDUCATIONAL SESSIONS AND METHODS WORK "MEET-THE-EXPERT" SUNRISE SESSIONS SHOPS (SATURDAY AFTERNOON, APRIL 10, 1999) DrugResistance(Susan P. C. Cole) To Be Announced Cancer Screening(Barnett S. Kramer) Molecular Signaling of CML (Jean Y. J. Wang) OFFICIAL OPENING EVENT (SUNDAY MORNING, Apoptosis and Chemotherapy (John A. Hickman) APRIL 11, 1999) Caspases (Nancy A. Thornberry) Presidential Address (Webster K. Cavenee) Molecular Cytogenetics (Joe W. Gray) Plenary Session: New Frontiers in Cancer Research p53 GeneTherapy-mediatedRadio/Chemosensitization(Esther H. Chang) Genetics (Robert A. Weinberg) The Genetics of Multiple Endocrine Neoplasia Type 2 (MEN 2) (Bruce A. J. Immunology and Vaccines (Lloyd J. Old) Ponder) Therapeutics and Translational Research (Judah Folkman) Differentiation Therapy (Samuel Waxman) Hormonal Intervention and Prevention (C. Kent Osborne) AIDS-related Malignancies (Ellen G. Feigal) AACR-Pezcoller International Cancer Research Award Lecture Tumor Vaccine Therapy (Michael T. Lotze) Special Lecture (James D. Watson) Integration of Biological Agents into Radiotherapy (William H. McBride) Molecular Detection of Minimal Residual Disease (Theodore F. Zipf) SYMPOSIA Microsatellite Instability (David Sidransky) Animal Models for Human Cancer: Recent Developments, New Chemoprevention Trials: Science vs. Art vs. Fantasy (David S. Alberts) Challenges (Tyler Jacks) Genetic Imprinting (Andrew P. Feinberg) Advances in Chemoprevention (Raymond N. DuBois) Cancer Metastasis: Cellular and Clinical Studies (David Tarin) Infectious Agents and Cancer (Nancy E. Mueller) Embryonal Stem-cell-based Technology (Randall Johnson) Ubiquitin and Protein Degradation (Alexander J. Varshavsky) Replicative Senescence (Judith Campisi) Genomics, Genetics, and New Approaches to Cancer (Richard D. Drug Design and Development (Randall K. Johnson) Klausner) In l'ivo Imaging of Gene Expression in Solid Tumors (Ralph Weissleder) Transcriptional Regulation and Cancer (Lorraine J. Gudas) The RB Family and CDKs in the Cell Cycle in Cancer (Antonio Giordano) Drug Discovery: From Basic Science to the Clinic (Daniel D. Von Hoff) Prospects for Biological Agents (Peter J. Houghton) Cancer Vaccines (Ronald Levy) Disorders in Cell Circuitry in Cancer (I. Bernard Weinstein) DNA Repair (Richard D. Kolodner) bcl2: Its Family and Modification (Timothy J. McDonnell) Telomeres, Centromeres, and Chromosomal Instability (Carol W. Topic to be Announced (Franklyn Prendergast) Greider) Chemoprevention in Respiratory Cancer (Lee W. Wattenberg) Basic and Clinical Approaches to Ovarian Cancer (Robert C. Bast, Jr.) TGF-ßand Colon Cancer (Sanford Markowitz) Gene Environment Interactions in Cancer Etiology (Margaret R. Spitz Inherited Susceptibility to Breast and Ovarian Cancers (Funmi I. Olopade) and Kenneth Olden) VEGF (Harold F. Dvorak) Apoptosis (Craig B. Thompson) Origins of Melanoma (Margaret A. Tucker) Molecular Targeted Therapy (John Mendelsohn) Biology of Premalignant Lesions (Walter N. Hittelman) Basic and Clinical Approaches to Lung Cancer (David Paul Carbone) Diet and Cancer: Process and Paradox (John D. Potter) Genetic Determinants of Prostate Cancer (William B. Isaacs) DNA Repair: Breaking Cycle-specific Constraints in Combination Therapy Genetic Instability, DNA Damage, and Checkpoint Regulation (Geoffrey (William K. Plunkett) Wahl) Invasion. Metastasis, and Angiogenesis (Isaiah J. Fidler) Antisense Therapies (Stanley T. Crooke) Drug Resistance and Cell Cycle Abnormalities (Joseph R. Bertino) Topic to be Announced (Nagahiro Saijo) Hormonally Related Tumors - Basic and Clinical Aspects (Bert W. Small Molecule Inhibitors of Protein Kinases That Block Tumor O'Malley and Marc E. Lippman) Angiogenesis for the Treatment of Cancer and Metastasis (Jerry Late Breaking Science (Waun Ki Hong and Webster K. Cavenee) McMahon) Topoisomerases in Carcinogenesis and Cancer Treatment (Leroy Fong Integration of Biological Agents into Chemotherapy (Herbert M. Pinedo) Liu) New Therapeutic Agents (Michaele C. Christian) Replication and the Cell Cycle (Jacqueline A. Lees) Function and Target Genes of myc in Neoplasia and Apoptosis (Chi Van Future Directions in Research on Tobacco and Cancer (Virginia L. Dang) Isolation of Genes Regulated by p53 or ß-cateninand Their Roles in Human Ernster) Advances in Stem Cell Gene Therapy (Cynthia E. Dunbar) Carcinogenesis(Vusuke Nakamura) BehavioralOncology(Barbara K. Rimer) FORUMS \liliN.!(Guillermina Lozano) Tamoxifen: Risks and Benefits Molecular Processes in DNA Repair After Irradiation (Gloria C. Li) Ethical and Legal Issues in Genetic Testing Natural Agents and Chemoprevention (Hirota Fujiki) The Genetics of Wilms Tumor (Michael R. DeBaun) Prevention and Treatment of Breast Cancer (Martin D. Abeloff) PROGRAM COMMITTEE Waun Ki Hong, Chairperson Carol W. Greider, Co-Chairperson Joseph F Fraumeni, Jr, Co-Chairperson Leroy F Liu, Co-Chairperson l-'urther Information AACR Office •Public Ledger Building, Suite 826 EDUCATION COMMITTEE • EXHIBITS COMMITTEE 150 S Independence Mall West • Philadelphia, PA 19106-3483 JetTrey M Trent, Chairperson David S Alberts. Chairperson LOCAL ARRANGEMENTS COMMITTEE Telephone: 215-440-9300« FAX 215-440-9313 Robert F Ozols, Chairperson E-mail: meetings:i/>aacr.org •Website: http://www.aacr.org msäa ResearchOpportunities At Amgen, you'll discover a research environment that emphasizes collaboration, intellectual honest)', scientific integrity, and a supportive ResearchAssociate (Job Code: 0000000138) culture. This unique approach has helped us grow into a global biotechnology leader in just 18 years. We are seeking research associates You will work with a select group of scientists who are discovering novel with a background in cancer-related research to work in our Cancer genes and examining signal transduction pathways that are altered during Biology program at Amgen. tumor genesis. We are seeking highly motivated individuals who are not only able to work efficiently in a team-oriented environment, but also ResearchScientist capable of designing experiments and thinking independently. You must (Job Code: 0000000137) possess technical experience in one or more ot the following areas: molecular biology, protein biochemistry, genomics, mammalian cell culture You will work in an exciting, fast-paced, state-of-the-art environment to and protein purification. A research background in apoptosís, angiogenesis, discover novel genes and pathways that regulate specific aspects of tumor cell cycle, ¡nvivo tumor models and tumor biology is preferred. A genesis. Positions are available for scientists with research experience in minimum of a Bachelor's degree in Science is required, a Master's degree or areas related to apoptosís, angiogenesis, cell adhesion, tumor biology and research experience in an academic or industrial setting is highly desirable. development of in vitro and in vivo assays for high-throughput screens. The cancer biology group collaborates with multiple groups within Amgen At Amgen, your accomplishments are rewarded. We orfer a highly including: protein chemistry, small molecule chemistry, high-throughput competitive compensation and benefits package that includes a retirement and savings plan, an on-site fitness center and three weeks' vacation. For screening, microarray and microprocessing, functional genomics and proteomics. The wide range ot resources available at Amgen enables immediate consideration, please mail your resume on plain white paper scientists to rapidly discover, characterize and validate potential therapeutic (indicating appropriate job code, using standard type and fonts, no bullets, targets. You must posses a Ph.D. in a molecular, biochemistry or cell italics, underlining or holding), to: Amgen, Staffing, P.O. Box 2569, Thousand Oaks, CA 91319-2569, or email your ASCII text resume to: biology program, with a minimum 3 years of postdoctoral experience in cancer-related research. A strong background in cancer research, a proven [email protected]. Please consult our Web Site at: www.amgen.com for publication track record, a drive to succeed and an ability to work in a information on other career opportunities available at Amgen. Principals team-oriented environment are key to your success. only, please. We recognize that diverse perspectives are a key in the process of discovery. EOE/AA Employer M/F/D/V. ¿MGEN Directorof Research ArkansasCancerResearchCenter Universityof Arkansasfor MedicalSciences The Arkansas Cancer Research Center (ACRC) at the University of Arkansas for Medical Sciences (UAMS) seeks nominations and applications for a Director of Research. Applicants must have an MD, PhD, or equivalent degree, and major administrative experience. He/she should have an active, funded program in basic and/or clinical cancer research. The candidate's scope, knowledge, and interest in cancer research should be sufficiently broad so that he/she can effectively interact with and facilitate the integration of the various research programs at the center. The Director of Research will oversee the overall development, coordination, and implementation of basic and clinical research at the ACRC. Specifically, the Director
Load more

Recommended publications
  • Harnessing the Power of Precision Oncology
    Cancer Advances Cleveland Clinic Cancer Center | Winter 2019 Harnessing the Power of Precision Oncology Ranked No. 5 in America for cancer care by U.S. News & World Report. Dear colleagues, Welcome to this issue of Cancer Advances. Our cover story features a sampling of our work in genetics and Advancing genomics, which is shifting the focus of questioning in oncologic research and care from tumor location to genetic mutation. Our researchers are approaching questions of cancer genetics from across the continuum, including detecting cancers at an earlier stage (p. 4), best Precision practices in testing for non-small cell lung cancer (p. 6), expanding the use of predictive assays (p. 7), treatments targeting individual tumor DNA (p. 8) and a new National Cancer Institute grant to study response prediction in Oncology radiation oncology (p. 10). Our leadership in developing the accreditation program for rectal cancer (p. 22) and the continued relevance and from Risk Prediction utility of the Khorana score (p. 14) showcase our ability to determine the line of inquiry at the national level. to Treatment Response Our multidisciplinary Sarcoma Program continues to investigate better treatments for this rare cancer while providing patients with a level of expertise matched by few centers in the United States (p. 16). Our work on potential new therapies for acute myeloid leukemia (p. 20) and breast cancer (p. 13) demonstrates the promising results of the continued pursuit of inquiry for our patients. Finally, we demonstrate our ability to ask complex questions with the work we’re pursuing on laser interstitial therapy with colleagues in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (p.
    [Show full text]
  • 2004 Albert B. Sabin Gold Medal Address Delivered by Award Recipient William S
    2004 Albert B. Sabin Gold Medal Address Delivered by Award Recipient William S. Jordan, Jr., M.D. With a Tribute by John R. LaMontagne, Ph.D. May 25, 2004 Arlington, Virginia INTRODUCTION by H.R. Shepherd, D.Sc. Chairman, The Albert B. Sabin Vaccine Institute he Sabin Vaccine Institute pursues Dr. Albert B. Sabin’s vision of a T world protected from disease by vaccines. The annual awarding of the Sabin Gold Medal has always been among our most meaningful traditions. The 2004 award was presented in May to an icon in vaccine research, William S. Jordan, Jr., M.D., at a ceremony in Arlington, Virginia, during the 7th Annual Conference on Vaccine Research, co-organized by the Sabin Vaccine Institute. The positive impact of vaccines on the health and well being of humanity continues to be a marvel of our modern world. Vaccine improvements, new vaccines, and vaccines in the pipeline represent an advancing field of science that brings untold preventive benefit to millions around the world. Along with his career in vaccine research, Dr. Jordan has engaged in compiling the record of scientific advancements in the field. His name is synonymous with both vaccine research and the compendium—The Jordan Report—that for 25 years has been a repository for advances in the vaccine field. The Sabin Gold Medal Advisory Committee, chaired by Maj. Gen. Philip K. Russell, M.D. (USA Ret.), selected Dr. Jordan for this honor after canvassing 300 members of the scientific community. We are pleased to recognize Dr. Jordan with this honor, noting his exemplary contributions in the vaccine field and commitment to lifesaving medical discoveries.
    [Show full text]
  • My Name Is Michael Mark Gottesman and My Position Is Deputy Director for Intramural Research at the National Institutes of Health
    NHGRI: OH_Gottesman_Michael_20111113 1 3/1/16 My name is Michael Mark Gottesman and my position is deputy director for intramural research at the National Institutes of Health. I was born on October 7, 1946 in Jersey City, New Jersey. And when I was around two years old, my family moved to Flushing, Queens, and I had most of my formative years growing up in Flushing. I cannot remember a time when I wasn’t interested in science. Probably the first interaction with issues related to public health was as one of many probably millions of children in the United States who got the Salk vaccine as a -- as a test. I remember lining up, they explained to us that this was a trial, and we all got shots, which was not that much fun for a six-year-old or a seven-year-old. And that was a huge sea change. I remember learning about the fact that before then people got polio, kids got polio. They wandered off to camp, they came back paralyzed. And after that period, we didn’t need to worry about polio. So I had the sense that there was a lot that biomedical research could do to alleviate human disease. The next big event scientifically in my life was the launch of Sputnik in 1957, and it was a wake-up call to the United States. We were so-called “falling behind” in the space race, and I was an eleven-year-old boy who was interested in space science. So I spent my childhood after that making rockets, probably not as safely as it should have been, but no unfortunate accidents befell me.
    [Show full text]
  • Fn Ee Rw Ms I
    FN EE RW MS I FERMILAB AU.S. DEPARTMENT OF ENERGY LABORATORY CDF Central Outer Tracker 10 Photo by Reidar Hahn Volume 23 INSIDE: Friday, May 26, 2000 Number 10 2 Sensenbrenner Visits Lab f 4 The DESYÐFermilab Connection 8 Next Phase of Wilson Hall Rehab 14 Letter to the Editor 14 Symposium on Fixed Target Program at the Tevatron House Science Committee Chairman James Sensenbrenner Jr. addresses the media after his tour of Fermilab. Opposite page: viewing a model of the lab site are (from left) Associate Director for Accelerators Steve Holmes, Sensenbrenner staffer Harlan Watson, Fermilab Director Michael Witherell and Chairman Sensenbrenner. by Mike Perricone Representative James Sensenbrenner Jr., (R-Wis.), chairman of the House Science Committee, left no one in the dark about his opinion of Fermilab. ÒFermilab is the jewel in the crown of scientific institutions in the United States,Ó Rep. Sensenbrenner said after a tour of the lab on March 15, including a visit to the manufacturing facility for superconducting magnets critical to the success of the Large Hadron Collider at CERN, the European particle physics laboratory in Geneva, Switzerland. Sensenbrenner: FERMILAB HAS Critical Role in Next Machine ÒSome of the other places IÕve been, IÕve seen big managerial problems and cost overruns,Ó he continued. ÒThatÕs not the case here, and thatÕs the way we want it to be. This place is well managed. Fermilab has a mission, and it accomplishes that mission.Ó Soon after becoming chairman of the science committee, Sensenbrenner played a critical role in the 1997 negotiations leading to the $531 million agreement for U.S.
    [Show full text]
  • Chironian Spring/Summer 2010
    Touro Scholar The Chironian NYMC Archives Publications Spring 2010 Chironian Spring/Summer 2010 New York Medical College Follow this and additional works at: https://touroscholar.touro.edu/nymc_arch_journals Part of the Higher Education Commons, and the Medicine and Health Sciences Commons Recommended Citation New York Medical College. (2010). Chironian Spring/Summer 2010. Retrieved from https://touroscholar.touro.edu/nymc_arch_journals/61 This Book is brought to you for free and open access by the NYMC Archives Publications at Touro Scholar. It has been accepted for inclusion in The Chironian by an authorized administrator of Touro Scholar. For more information, please contact [email protected]. New York Medical c o l l e g e c h i r o N i a N S p r i N g / S u mm e r 2 0 1 0 “In the coNtiNual reMeMbraNce of a gloriouS paSt, iNdiVidualS aNd Nations fiNd their NobleSt inspiratioN.” —Sir williaM Osler, aequaNiMitaS 1 8 6 0 – 2 0 1 0 c h i r o N i a N S p r i N g / S u mm e r 2 0 1 0 FEATURES ALUMNi NEWS — A TIMELINE OF NEW YORK MEDICAL 22 NOURISHING THE BONDS THAT KEEP COLLEGE HISTORY THE COLLEGE STRONG by Donna E. Moriarty, M.P.H. ’04 and by Andrea Kott, M.P.H. Kimberly Gaudin de Gonzalez 25 SIMULATED PATIENTS, 1 A LETTER TO THE COMMUNITY REAL PRACTICE by Karl P. Adler, M.D. and Ralph A. O’Connell, M.D. by Lynda McDaniel 2 PROTECTING CHILDREN, 26 MILESTONES INFORMING CAREGIVERS by Marjorie Roberts 26 KEEPING FIRST RESPONDERS “COMMUNICADO” by Lynda McDaniel 6 COUNTERING CHEMICAL THREATS: THE FINE ART OF HARD SCIENCE HE’LL TAKE MANHATTAN (AGAIN) by Marjorie Roberts 28 by Lynda McDaniel 9 LYME DISEASE: LEADERS, LANDMARKS, AND LOOKING AHEAD 30 2010 COMMENCEMENT & REUNIONS by Cynthia A.
    [Show full text]
  • November 3, 1998, NIH Record, Vol. L, No. 22
    R E C 0 R Still The Second Best Thing About Payday Budding Young Scientists Aim HI H.t: 1 G H Life, Death and Everything in Between For the Stars Research Festival 12 a Big Draw By Kimberly C. Mitchell Ever heard a 10-year-old kid describe the Research Festival t was as if some giant had grabbed the NIH campus by the mechanics of jet propulsion? Or the Packs 'em In corner up near the firehouse on Old Georgetown Rd. and tilted principles behind refracted light? That's Iit so that everything slid helplessly toward the Natcher Bldg. what some Now THAT's a Oct. 6-9 as the twelfth version of Research Festival (originally youngsters Budget! only a daylong event) drew many can do after hundreds of NIH'ers to a ravishing feast spending 6 of intramural science. For a 3-day months in stretch, Natcher and its environs were to Eleven Elevate to science what Bethesda is to restaurants­ the AAAS Fellowhood Adventure a teeming smorgasbord of tasty possibili­ in Science ties. (AIS) It became almost comical, after a day or program. Get Ready for two, to see literally hundreds of pre-, Quality of Work . .... From post- and postpostdocs fleeing the , Life Week Dr. Rebecca Hackett helps a October to crowded morning plenary sessions for student prepare to measure March of one of dozens of workshops held in NASA Administrator the uptake of water and each year, various nooks and warrens within the nutrients through the root Daniel Goldin opens sprawling Natcher complex. All adopted these young session on origins of /ife.
    [Show full text]
  • NCI Budget Fact Book for Fiscal Year 1996
    NCI FACT BOOK National Cancer Institute 1996 U.S. DEPARTMENT NATIONAL INSTITUTES OF HEALTH AND OF HEALTH HUMAN SERVICES The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892. TABLE OF CONTENTS Page Organization Director's Biography ........................................ 1 Former Directors of the NCI .................................. 2 National Cancer Advisory Board .............................. 3 Division Boards of Scientific Counselors ........................ 4 President's Cancer Panel .................................... 5 Executive Committee Members ............................... 5 Organization Charts: National Cancer Institute ................................... 6 Office of the Director ...................................... 7 Division of Basic Sciences .................................. 8 Division of Clinical Sciences ................................ 9 Division of Cancer Epidemiology and Genetics ................. 10 Division of Cancer Prevention and Control .................... 11 Division of Cancer Treatment, Diagnosis and Centers ............ 12 Division of
    [Show full text]
  • The Physiologist
    A Publication of The American Physiological Society Experimental The Biology 2001 Abstract Physiologist Deadline Volume 43, Number 4 August 2000 November 6! EB 2001—Translating the Genome On June 26th, President Clinton walked into denced by their titles. Others will include talks the White House East Room and announced “the by leading scientists using genomics to define most wondrous map ever produced by the physiological function of a cell or a tissue. humankind.” The efforts of a public consortium However, the sessions listed are only those being led by Francis Collins and the private efforts of offered by APS. In the future, The Physiologist, Craig Venter, Celera Genomics, created a “Book the Call for Abstracts (to be mailed in of Letters,” a readout of the 3.1 billion biochem- September), and the EB and APS Home Pages ical “letters” of human DNA. These letters, will provide a listing of the wide range of ses- Inside which provide the coded instructions for a fully sions related to the “omics” listed above. functional human, will remain undecipherable However, as you are well aware, the APS por- until they are combined into words and sentences tion of the Experimental Biology meeting is not 153rd APS with meaning. just about “Translating the Genome.” It is about Business Just as APS created a new journal, all of physiology from cellular and molecular to Meeting Physiological Genomics, to provide a forum for integrative and systems to translational and clin- p. 168 the dissemination of information about the trans- ical application. It is also about professional lation of the “Book of Letters” arising from the development and social interactions.
    [Show full text]
  • A Review of Judah Folkman's Remarkable Achievements
    RETROSPECTIVE A review of Judah Folkman’s remarkable achievements in biomedicine Yihai Cao*† and Robert Langer‡ *Department of Microbiology and Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden; and ‡Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139 n January 14th of this year, the biomedical research com- munity lost Judah Folkman, O the father of angiogenesis research. Folkman’s warm and humble personality, inspirational teaching, un- limited creativity, and vast clinical expe- rience have been described elsewhere (1). Here, we focus on Folkman’s in- effaceable scientific achievements in angiogenesis research, which revolution- ized biomedical research and clinical drug development. Folkman founded an entirely new field of basic and clinical research and discovered a previously unknown family of angiogenesis regulatory molecules. He showed experimentally how these molecules provide a fundamental mech- anism that controls the growth of virtually all tumors. He showed that expansion of tissue mass, whether Judah Folkman. (Image courtesy of Jon Chase/Harvard News Office.) neoplastic or nonneoplastic, critically depends on continuous endothelial rep- This 1971 report was the first to intro- the cornea, a methodology that was crit- lication and neovascularization. duce the concept of a novel form of tu- ical for proof of angiogenic bioactivity Those discoveries paved new avenues mor dormancy caused by blockage of of a given molecule in vivo (5). His re- for the development of a new class of angiogenesis. In that paper, Folkman search also identified the existence of a drugs, angiogenesis inhibitors, which have also introduced the concept of ‘‘anti- family of angiogenic peptides (6), and already provided novel therapies for hu- angiogenesis’’ as a potential novel anti- he showed that removing an angiogenic man cancer and age-related macular cancer therapy.
    [Show full text]
  • Cuadernos De Divulgación Científica Sebbm "Acércate a Nuestros Científicos 2015-2017"
    CUADERNOS DE DIVULGACIÓN CIENTÍFICA SEBBM "ACÉRCATE A NUESTROS CIENTÍFICOS 2015-2017" Imagen: Pinacoteca de la Ciencia. Contaminación (probablemente un hongo) en una rodaja de cerebro en cultivo. Autor: Javier Díaz (Dpto. de Bioquímica y Biología Molecular I, Universidad Complutense de Madrid). ÍNDICE DE CONTENIDOS 1. Enero 2015: Especial Premio Nobel de Química 2014: El nanoscopio (Cristina Flors)..................................................................................................................... pp. 4-5 2. Febrero 2015: Especial Premio Nobel Medicina 2014: De disparos y oscilaciones (Liset Menéndez de la Prida)................................................................................ pp. 6-7 3. Marzo 2015: Especial Premio Nacional de Investigación en Medicina “Gregorio Marañón” 2014: Jesús Prieto: Conocer el hígado para curarlo (Carmen Berasain)............................................................................................................... pp. 8-9 4. Marzo 2015 (2): Ceramidas: no sólo en las cremas de belleza (Alicia Alonso).............................................................................................................. pp. 10-11 5. Abril 2015: Citostasis y metástasis en cáncer (Francesc Ventura)............... pp. 12-13 6. Mayo 2015: Nuevos avances en la regulación redox del ciclo de la metionina (María de los Ángeles Pajares Tarancón).................................................................... pp. 14-15 7. Junio 2015: El reloj circadiano de Arabidopsis thaliana: ¡las plantas
    [Show full text]
  • Judah Folkman Judah Folkman Was Born Moses Judah Folkman in 1933
    Judah Folkman Judah Folkman was born Moses Judah Folkman in 1933. The son of a rabbi, he became inspired to become a physician as a young boy when visiting ailing members of the congregation with his father. He soon became fascinated with science and medicine, and as a high school student he devised a perfusion system in his basement that maintained the viability of a beating rat heart for days after surgical removal. This led to his admission at age 15 to nearby Ohio State University, where Judah worked part-time all four years in the surgical laboratory of Dr. Robert Zollinger. He quickly mastered surgical skills and became an active participant in the exciting world of academic surgery. Judah entered Harvard Medical School at 19, where he was welcomed into the laboratory of Dr. Robert Gross, then Surgeon-in-Chief at Children’s Hospital. There, he invented the first implantable heart pacemaker. Based on his scientific contributions, Judah was elected to the AOA and received the Boylston Medical Prize, Soma Weiss Award, and Borden Undergraduate Research Award in Medicine, when he graduated magna cum laude from HMS in 1957. Judah became a surgical resident at Massachusetts General Hospital where he had his first introduction to Pediatric Surgery under the mentorship of Dr. W. Hardy Hendren. Midway through his residency, Judah married the love of his life, Paula Prial, who was to become the mother of his wonderful daughters, Marjorie and Laura, and his closest confidant for the remainder of his life. Soon thereafter, Judah enlisted in the United States Navy to fulfill his military obligations for two years.
    [Show full text]
  • Judah Folkman 1933–2008
    Judah Folkman 1933–2008 A Biographical Memoir by Patricia K. Donahoe ©2014 National Academy of Sciences. Any opinions expressed in this memoir are those of the author and do not necessarily reflect the views of the National Academy of Sciences. MOSES JUDAH FOLKMAN February 24, 1933–January 14, 2008 Elected to the NAS, 1990 Moses Judah Folkman was born in 1933 in Cleveland, Ohio. He was the oldest child of a distinguished line of rabbis whose influence on the young man—particularly that of his father, Rabbi Jerome Folkman—is legendary. His mother, Bessie Schomer Folkman, instilled in him a love of science with bedtime stories about Newton, Pasteur, and Madame Curie. A move to Columbus during high school put Folkman under the tutelage of Robert Zollinger, who spotted him working at Ohio State University Hospital as a volunteer aide and invited him to work in his laboratory afternoons and weekends. There in the Zollinger Laboratory, where he worked throughout college, Folkman had the oppor- By Patricia K. Donahoe tunity to learn surgical skills and published a paper about liver cooling in the journal Surgery. He was accepted at Harvard Medical School in 1953 and worked in the laboratories of Robert E. Gross, from whom he learned the “obsessive perseverance” required for his future life as a surgeon scientist. Folkman also helped to develop a heart-lung bubble oxygenator, which was initially used for repair of ventricular septal defects, and he designed a prototype transistorized pacemaker with Massachusetts Institute of Technology graduate student Fred Vanderschmidt. The heart lung machine and the pacemaker, though perfected in other laboratories, provided the tools to realize Gross’s dream of innovating and making cardiac surgery routine for infants and children (Cooke 2001).
    [Show full text]